TRACON Pharmaceutical (TCON) Enters Oncology Assets Licensing Collaboration with Janssen
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
TRACON Pharmaceutical (TCON) Offers Additional Detail on Janssen Licensing Agreement
September 28, 2016 4:41 PM EDTTRACON Pharmaceutical (NASDAQ: TCON) disclosed the following in a U.S. SEC filing on Wednesday:
Item 1.01 - Entry into a Material Definitive Agreement.
On September 27, 2016, TRACON Pharmaceuticals, Inc. (the Company) entered into separate transactions with Janssen Pharmaceutica N.V. (Janssen) and its affiliate, Johnson & Johnson Innovation-JJDC, Inc. (JJDC) consisting of a license and option agreement with Janssen (the License and Option Agreement) and a stock purchase agreement and investor agreement, each with JJDC (the Stock Purchase Agreement and the Investor Agreement, respectively).
License and Option Agreement
Under the License and Option Agreement, Janssen granted the... More
Janssen-Cilag Will Present Oncology Data at ESMO 2016
September 28, 2016 11:17 AM EDTJanssen-Cilag International NV announced data from ten company-sponsored abstracts will be presented at the 2016 ESMO Congress in Copenhagen, Denmark, on the 9th and 10th October 2016. The data feature four Janssen medicines spanning multiple disease areas including prostate, urothelial and blood cancer, and showcase Janssens broad portfolio in oncology and commitment to patients.
The data to be presented at ESMO highlights the efficacy and safety profiles of Janssen treatments and also provides insights from a large, real-world prostate cancer patient population on how patients live with, and manage, their disease. Every patient with cancer will face his or... More